Imgatuzumab

Imgatuzumab is a monoclonal antibody designed for the treatment of cancer. This drug was developed by Roche.

Mechanism of Action

Imgatuzumab works by binding to the epidermal growth factor receptor (EGFR), which is overexpressed in many types of cancer. By binding to EGFR, imgatuzumab inhibits the growth and proliferation of cancer cells.

Clinical Trials

Imgatuzumab has been tested in several clinical trials for various types of cancer, including colorectal cancer, lung cancer, and head and neck cancer. However, the results of these trials have been mixed, and the drug is not currently approved for use in any country.

Side Effects

Like all drugs, imgatuzumab can cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, and rash. In rare cases, imgatuzumab can cause serious side effects, such as lung disease and heart problems.

Future Research

Research is ongoing to determine the best use of imgatuzumab in cancer treatment. This includes determining which types of cancer respond best to the drug, as well as identifying potential biomarkers that can predict a patient's response to imgatuzumab.

See Also

• Monoclonal antibodies
• Epidermal growth factor receptor
• Clinical trials
• Cancer treatment